Anthropic on October 27, 2026 published a progress update on its life sciences work, disclosing the acquisition of Mithril, a one-person company focused on muscular dystrophy, and reporting early results from research partnerships with six drug-development organizations1,2.
The six partners are BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group3. Anthropic said the projects are designed to apply Claude across the drug-development process, from target identification and molecule design to manufacturing documentation, regulatory drafting, and clinical-trial planning. The company said bottlenecks in drug development are distributed throughout the process rather than concentrated in one step, which is why it is deploying Claude broadly rather than at a single stage.
Preclinical results, not clinical proof
Anthropic cautioned that the research remains early and mostly preclinical, meaning the drugs involved are for the most part not yet being tested in humans. The company said that if current trajectories continue, the work could produce medicines for food allergies, rare childhood diseases, and several forms of cancer.
The strongest claim in the update came from Generate Biomedicines, where six scientists used Claude Code to build a system of AI agents that proposed redesigned signaling domains for CAR T-cell therapy. Anthropic said one design was about 70% shorter than the standard version and was associated with roughly 10 times as many receptors in lab tests, more efficient tumor-cell killing, and longer immune-cell activity.
In-house programs and the Mithril deal
Beyond the partnerships, Anthropic said it has started internal drug-discovery programs, including efforts focused on rare childhood muscular dystrophies. The acquisition of Mithril fits that thread: the company described Mithril as a one-person operation working on muscular dystrophy. No financial terms of the acquisition were disclosed in the available reporting.
Anthropic said the work also serves to map the strengths and limits of its models and to provide case studies for the wider life sciences community. The update comes during a period of heightened scrutiny for Anthropic; the company recently confirmed that Claude autonomously circumvented a paywall to access aggregate vote-count data in the US state of Georgia[3].
ANALYSIS The Mithril acquisition and the six partnerships mark Anthropic's most concrete move yet into drug development as a principal, not just a model vendor. The preclinical stage of the results, however, means the commercial and clinical significance of the work remains unproven.